# Signal & Risk Management Fact Sheet

- Fact Sheets, Resources  
- February 1, 2024

Qinecsa provides tailored signal detection and risk management services for clinical and commercial products, including associated benefit-risk management activities. With diverse therapeutic expertise and industry-leading technology, our team support the breadth and depth of signal evaluation and risk management obligations.

## Recent News & Events

### [Join Qinecsa at World Patient Safety Congress Americas 2026 in Boston](/content/events/join-qinecsa-at-world-patient-safety-congress-americas-2026-in-boston/index.html)

- September 18, 2026

### [Join Qinecsa at World Patient Safety Congress Europe 2026 in Amsterdam](/content/events/join-qinecsa-at-world-patient-safety-congress-europe-2026-in-amsterdam/index.html)

- September 18, 2026

### [Qinecsa selected as technology partner for Africa’s new continent-wide medicines safety platform](/content/news/qinecsa-selected-as-technology-partner-for-africas-new-continent-wide-medicines-safety-platform/index.html)

- September 10, 2026

### [Qinecsa Solutions Appoints Healthcare and Technology Leader Willem Baralt as Chair of the Board](/content/news/qinecsa-solutions-appoints-healthcare-and-technology-leader-willem-baralt-as-chair-of-the-board/index.html)

- September 8, 2026

### [Qinecsa Releases HaloPV 6.2 to Strengthen Global Pharmacovigilance Compliance and Platform Stability](/content/news/qinecsa-releases-halopv-6-2-to-strengthen-global-pharmacovigilance-compliance-and-platform-stability/index.html)

- April 29, 2026

### [Qinecsa signals next growth chapter with appointment of Alex Livingstone-Learmonth as Chief Commercial Officer](/content/news/qinecsa-signals-next-growth-chapter-with-appointment-of-alex-livingstone-learmonth-as-chief-commercial-officer/index.html)

- January 12, 2026